DREAMM-2, the pivotal open-label, randomised study of two doses of belantamab mafodotin has reported a clinically meaningful overall response rate (ORR) in relapsed myeloma patients.
The 196 patients in the trial had relapsed myeloma, were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody. The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin in the patient population, according to a press release from GlaxoSmithKline (GSK). The safety and tolerability profile was consistent with that observed in DREAMM-1, the first-in-human study of belantamab mafodotin.
Safety and efficacy results from the DREAMM-2 study will be submitted for presentation at an upcoming scientific meeting. Additional ongoing studies are testing the effect of belantamab mafodotin as third-line monotherapy in relapsed/refractory myeloma and as a combination treatment in the first and second line setting as part of the broader DREAMM clinical development programme.
